GENETIC ANALYSIS OF HEMOPOIETIC HISTOCOMPATIBILITY

造血组织相容性的遗传分析

• 批准号: 3197273
• 负责人: ICHIRO NAKAMURA
• 金额: $ 18.17万
• 依托单位: STATE UNIVERSITY OF NEW YORK AT BUFFALO
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-04-01 至 1994-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3197273
• 关键词: chromosome walking; genetic library; genetic mapping; genetic recombination; genetically modified animals; haploidy; hematopoietic tissue transplantation; histocompatibility; histocompatibility gene; homologous transplantation; immunogenetics; laboratory mouse; major histocompatibility complex; molecular cloning; natural killer cells; northern blottings; nucleic acid probes; restriction fragment length polymorphism; southern blotting; transfection

DESCRIPTION: (Adapted from the applicant's abstract) The long-term objective of this project is to understand the genetic mechanism(s) underlying the natural resistance to hemopoietic allografts. As an initial approach towards the stated objective, three specific aims are proposed: 1) to determine the location of the Hh-1 locus in the H-2-b and H-2-d chromosomes by determining restriction fragment length polymorphism (RFLP) in a panel of H-2S/D recombinant haplotypes, 2) to identify and isolate the Hh-1 genes, using human and murine probes for the H-2S/D interval and H-2-b and H-2-d cosmid libraries, and 3) to initiate the characterization of the genes thus identified. The proposed approach should provide new insight into the genetic mechanism underlying natural resistance and the recognition function of NK cells. In addition, these studies should help identify homologous genes in man, improve the prospect of clinical bone marrow transplantation, and possibly develop NK cell-mediated cancer immunotherapy.

描述：（改编自申请人的摘要）长期 该项目的目的是了解遗传机制 对垂直同种异体移植的自然抗性的根本。 作为初始 提出了既定目标的方法，提出了三个具体目标： 1）确定HH-1基因座在H-2-B和H-2-D中的位置 通过确定限制片段长度多态性（RFLP）来确定染色体 在一组H-2S/D重组单倍型中，2）识别和分离 HH-1基因，使用人和鼠探针进行H-2S/D间隔和H-2-B 和H-2-D Cosmid库，以及3）启动表征 因此鉴定出基因。 拟议的方法应提供新的见解 进入自然抵抗的遗传机制和 NK细胞的识别函数。 此外，这些研究应该有助于 识别人类中的同源基因，改善临床骨的前景 骨髓移植，并可能发展为NK细胞介导的癌症 免疫疗法。